Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — FY2020/21 Earnings Presentation
10 slides from Coloplast A/s Class B's earnings presentation, 2021
Slide 1: Making life easier
c Conference call presentation FY 2020/21 Making life easier Kristian, IC device user STRIVE25: SUSTAINABLE GROWTH LEADERSHIP Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid FY 2020/21 results with organic growth of 7% and 33% EBIT margin
Solid FY 2020/21 results with organic growth of 7% and 33% EBIT margin1) despite a challenging year due to COVID-19 REVENUE GROWTH FY 2020/21 Highlights Reported revenue (mDKK) +5% • Organic growth of 7% and reported growth in DKK of 5% (10% organic growth in Q4) Organic growth • Organic growth by b
Slide 4: Solid progress on Strive25 strategy – Sustainable Growth Leadership
Solid progress on Strive25 strategy – Sustainable Growth Leadership Growth Innovation . US Chronic Care Chronic Care – Clinical Performance Programme - Expanded the Ostomy Care sales force to capitalise on the GPO access - Initiated payer pilot studies on the Digital Ostomy Tool in Germany and the U
Slide 5: FY 2020/21 growth was broad-based, driven by the resumption of hospital activity
FY 2020/21 growth was broad-based, driven by the resumption of hospital activity across business areas and geographies FY 20/21 revenue by business area FY 20/21 revenue by geography Business Reported revenue FY Organic growth Share of organic Geographic Reported revenue FY Organic growth Share of o
Slide 6: FY 2020/21 reported revenue was up 5%, impacted by the depreciation of the USD
FY 2020/21 reported revenue was up 5%, impacted by the depreciation of the USD and Emerging market currencies FY 2020/21 Revenue development (DKKm) FY 2020/21 Highlights • Reported revenue increased by DKK 882 million. Organic growth was 7% or DKK 1,308 million 1,308 23 -450 • Main drivers of perfor
Slide 7: FY 2020/21 reported EBIT margin of 33% driven by efficiency gains
FY 2020/21 reported EBIT margin of 33%1) driven by efficiency gains and lower commercial spending due to COVID-19 FY 2020/21 EBIT margin development (%) FY 2020/21 Highlights • Gross margin was 69% compared to 68% last year 33.2 • Positive impact from leverage on production costs and 0.2 -0.1 0.1 32
Slide 8: FCF driven by solid underlying development in earnings
FCF driven by solid underlying development in earnings FCF development Comments FY 2020/21 Highlights • Free cash flow was DKK 3,279 million compared to DKK 3,858 million in FY 2019/20 98 99 98 93 93 • Adjusting for the acquisition of Nine Continents Medical, the free 90 cash flow for FY 2020/21 was
Slide 9: Organic growth guidance for FY 2021/22
Organic growth guidance for FY 2021/22 GUIDANCE 2021/22 GUIDANCE 2021/22 (DKK)* KEY ASSUMPTIONS • Continued resumption of hospital activity across business areas • Chronic Care: continued improvement in growth in Europe, as a result of normalized growth in new patients in line with pre-COVID levels;
Slide 10: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /